Clinical Trials Browser

Phase 3 × Active not recruiting × Ovarian Neoplasms × Clear all

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Pathologic Complete Response, Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Melanoma, Ovarian Neoplasms, Sarcoma, Pyloric Stenosis, Hypertrophic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Clinical Trials

ROSY-O

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

OVHIPEC-2

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

FLORA-5

Avelumab Program Rollover Study

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

CHIPPI

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

KEYNOTE-B96

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

RAINFOL-02

MONO-OLA1

KOV-HIPEC-02R

FLAMES

FIRST

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

SOLO-1

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

KEYLYNK-001

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

DUO-O

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer